This suggests that patients with MYCN-amplification might benefit the most from anti-GD2 treatment which significantly activates PHLDA1 expression, at least in IMR-32 neuroblastoma cell line (Horwacik et al., 2015). This evidence concerns the gene PHLDA1 and neuroblastoma.